Table 3.
The Results of the Meta-Analysis.
| Number of Studies | Patients | HR (95% CI) | Heterogeneity (I 2, P) | |
|---|---|---|---|---|
| Overall survival | ||||
| All | 15 | 4146 | 0.59 (0.50-0.69) | 32.0%, 0.113 |
| Asian | 5 | 1352 | 0.67 (0.50-0.91) | 50.4%, 0.089 |
| Western | 10 | 2794 | 0.56 (0.46-0.67) | 20.9%, 0.251 |
| Gene | ||||
| MMR | 10 | 3539 | 0.58 (0.45-0.75)a | 47.3%, 0.047 |
| hMSH2 | 4 | 496 | 0.48 (0.30-0.77) | 0.0%, 0.805 |
| hMLH1 | 1 | 111 | 0.29 (0.10-0.87) | NR |
| Test method | ||||
| IHC | 11 | 3084 | 0.51 (0.42-0.62) | 9.7%, 0.351 |
| PCR | 4 | 1062 | 0.74 (0.57-0.96) | 33.4%, 0.212 |
| Disease-free survival | ||||
| All | 10 | 2312 | 0.62 (0.44-0.88) | 66.5%, 0.001 |
| Allb | 9 | 2239 | 0.57 (0.43-0.75) | 48.0%, 0.052 |
| Asian | 6 | 1305 | 0.62 (0.50-0.78)a | 61.9%, 0.022 |
| Western | 3 | 934 | 0.55 (0.38-0.81) | 0.0%, 0.373 |
| Gene | ||||
| MMR | 4 | 1456 | 0.61 (0.47-0.79) | 0.0%, 0.493 |
| hMLH1 | 2 | 421 | 0.32 (0.17-0.58)a | 79.2%, 0.028 |
| hMSH2 | 3 | 362 | 0.72 (0.52-1.00) | 25.5%, 0.261 |
| Test method | ||||
| IHC | 8 | 2145 | 0.62 (0.51-0.76) | 5.3%, 0.389 |
| PCR | 1 | 94 | 0.06 (0.01-0.30) | NR |
Abbreviations: IHC, immunohistochemistry; NR: not report; MMR, mismatch repair; PCR, polymerase chain reaction.
a Results from random-effect model.
b Bendardaf study was excluded, which was also excluded in subgroup analysis.